Cassava Sciences (NASDAQ:SAVA) 주식

CASSAVA SCIENCES INC

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

bulls-and-bears-25ai

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

Short Ideas

Trading Ideas

$BTC

AMZN

MSTR

PLTR

RIVN

SAVA

TSLA

벤징가는 지난주 많은 투자자들이 선호하는 주식들의 전망을 조사한 결과를 바탕으로, 다음과  같이 주요 뉴스 몇 가지를 요약했다. 다우 지수가 1.4% 상승하여 11월 상승률을 7.5%로 끌어올린 반면, S&amp;P 500과 나스닥 종합지수는 각각 1.1% 상승하여 월간 상승률이 각각 5%와 6%를 넘어서며 다우와 S&amp;P 500의 2024년 최고의 월간 실적을 기록했다.

벤징가 불스 앤 베어스: 아마존, 테슬라, 리비안, 팔란티어 그리고 도지코인

Microstrategy, Marathon Digital Holdings, Coinbase, Cleanspark, And Tesla: 5 Stocks On Investors' Radars Today Amid Bitcoin Buzz

News

Markets

월요일(25일) 미국 증시는  S&amp;P 500 지수와 다우존스 지수가 사상 최고치를 경신하며 역사적인 하루를 보냈다. 러셀 2000 지수 역시 글로벌 지정학적 긴장 완화, 대선 이후 강세 모멘텀, 계절적 호재에 힘입어 사상 최고치를 기록했다. 하지만 비트코인과 금은 하락세를 보였다.

월요일 주목받은 주식: 카사바 사이언스, 줌, 콜스, 리비안 및 테슬라

Friday's Top 5 Trending Stocks

Biotech

Large Cap

Topics

Movers

General

AVXL

CHWY

SOFI

게임스탑(NYSE:GME), 소파이 테크놀로지스(NASDAQ:SOFI), 테슬라(NASDAQ:TSLA), 카사바 사이언스(NASDAQ:SAVA) 및 아나벡스 라이프 사이언스(NASDAQ:AVXL)는 금요일 스탁트위츠(Stocktwits)에서 가장 많이 언급된 상위 5개 종목이다. 무엇이 소매 투자자들의 주목을 받았는지 살펴보겠다.

금요일 상위 5개 트렌드 주식: 게임스탑, 소파이, 테슬라, 카사바 및 아나벡스에 대한 소식은?

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

SAVANNAH ENERGY PLC by Savannah Energy Plc

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

WIIM

RILY

B. Riley Financial shares are trading higher after the company sold its advisory services businesses, GlassRatner Advisory & Capital Group and B. Riley Farber Advisory, to funds managed by TorQuest Partners for $117.8 million.

Canaccord Genuity analyst Joseph Vafi maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

Price Target

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Maintains Buy on Core Scientific, Maintains $17 Price Target

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk endorsed&nbsp;Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Satya Nadella&#8217;s&nbsp;perspective on&nbsp;the practical impact of AI, emphasizing its&nbsp;benefits to sectors like healthcare,&nbsp;education, and productivity.
What Happened: Musk, on X, supported Nadella&#8217;s views on AI&#8217;s progress, which were shared in a post by Nadella on June 25, 2025. Nadella, the CEO of&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), had stressed the importance of AI&#8217;s real-world outcomes over technical benchmarks at Y Combinator&#8217;s&nbsp;AI Startup School wherein Elon Musk commented &#8220;True&#8221;. Nadella stated that AI must produce results that are &#8220;socially useful.&#8221;
This shift in focus aligns with recent studies indicating AI&#8217;s&nbsp;potential to enhance GDP growth&nbsp;by addressing real-world challenges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">True <a href="https://t.co/iFlmTUzLwx">https://t.co/iFlmTUzLwx</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1938086636941939098?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;If we really are not creating social surplus, economic surplus, as measured by countries and communities, we just can&#8217;t consumer energy.&#8221; stated Nadella. 
&#8220;The real question in the next five years is we&#8217;ve got to produce enough products that are creating great value,&#8221; he added.
He also pointed out&nbsp;that the true measure of&nbsp;AI&#8217;s progress lies in&nbsp;its ability to improve real-world&nbsp;outcomes rather than just achieving&nbsp;technical benchmarks. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46131453/bitcoin-ethereum-rangebound-dogecoin-dips-amid-potential-july-tariff-deadline-extension-analyst-predicts-btcs-next-big-move-once-it-breaks-out-of-this-range" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Rangebound, Dogecoin Dips Amid Potential July Tariff Deadline Extension: Analyst Predicts BTC&#8217;s &#8216;Next Big Move&#8217; Once It Breaks Out Of This Range </a>
Why It Matters:&nbsp;Musk&#8217;s endorsement of Nadella&#8217;s view on AI&#8217;s real progress comes at a time when the tech industry is witnessing a shift towards focusing on&nbsp;the practical impact of AI.
CEO Satya Nadella believes that while AI is already <a href="https://www.benzinga.com/markets/tech/25/06/46111393/ai-is-already-speeding-up-discoveries-in-chemistry-and-physics-but-satya-nadella-says-the-real-breakthrough-will-come-when-we-add-quantum-computing-to-the-mix">driving major</a> scientific breakthroughs, its full transformative potential will be unlocked with the integration of quantum computing. Meanwhile, the growing role of AI in healthcare was highlighted, with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partnering with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to speed up drug discovery and development. 
However, Wall Street remains divided on AI's future—while some investors are optimistic about its disruptive potential, others express concerns over associated risks and the lack of transparency in how it is being managed.
On a year-to-date basis, ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) climbed 24.85% and 13.05%, respectively. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46127671/amazon-loses-top-ai-leader-in-high-stakes-talent-shuffle">Amazon Loses Top AI Leader In High-Stakes Talent Shuffle </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARKK

MSFT

NVDA

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) will release earnings results for the first quarter after the <a href="https://www.benzinga.com/quote/STZ/earnings">closing bell on Tuesday, July 1.</a>
Analysts expect the company to report quarterly earnings at $3.29 per share, down from $3.57 per share in the year-ago period. Constellation Brands projects to report quarterly revenue at $2.56 billion, compared to $2.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, Barclays analyst Lauren Lieberman maintained a Constellation Brands rating of Overweight and lowered the price target from $207 to $202. JP Morgan analyst Andrea Teixeira maintained the stock with a Neutral rating and cut the price target from $194 to $170.
With the recent buzz around Constellation Brands, some investors may be eyeing potential gains from the company's dividends too. As of now, Constellation Brands offers an annual dividend yield of 2.53%, which is a quarterly dividend amount of $1.02 per share ($4.08 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $237,302 or around 1,471 shares. For a more modest $100 per month or $1,200 per year, you would need $47,428 or around 294 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.08 in this case). So, $6,000 / $4.08 = 1,471 ($500 per month), and $1,200 / $4.08 = 294 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
STZ Price Action: Shares of Constellation fell 0.1% to close at $161.32 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a></li>
</ul>
Photo: The Image Party/Shutterstock

Earnings

Dividends

How To Earn $500 A Month From Constellation Brands Stock Ahead Of Q1 Earnings

Chinese electric vehicle manufacturer Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) stock traded lower on Friday after the company cut its delivery outlook for the <a href="https://www.benzinga.com/pressreleases/25/06/g46133821/li-auto-inc-updates-second-quarter-delivery-outlook" target="_blank" rel="noreferrer noopener">second quarter of 2025</a>.
This adjustment closely follows <a href="https://www.benzinga.com/markets/asia/25/06/46132552/telsla-model-y-rival-xiaomi-yu7-suv-receives-nearly-300000-orders-in-1-hour-in-china">Xiaomi&#8217;s successful YU7 SUV</a> launch, which aggressively undercut rivals like Tesla&#8217;s Model Y and intensified competition in the Chinese EV market.
Li Auto now anticipates delivering approximately 108,000 vehicles in the second quarter of 2025, which represents a 0.5% year-on-year decline.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/45881963/tesla-supplier-catl-hits-milestone-with-1-million-battery-packs-delivered-to-li-auto" rel="noreferrer noopener">Tesla Supplier CATL Hits Milestone With 1 Million Battery Packs Delivered To Li Auto</a>
This is a significant reduction from its <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45667278/li-auto-q1-vehicle-deliveries-jump-15-continues-high-cash-burn" rel="noreferrer noopener">previous forecast</a> of 123,000-128,000 vehicles, which would have represented a 13.3%-17.9% year-on-year increase.
For context, Li Auto reported total vehicle deliveries of 108,581 units in the fiscal <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40595804/chinese-ev-maker-li-auto-q2-earnings-eps-beat-25-deliveries-growth-margin-struggles-and-more" rel="noreferrer noopener">second quarter of 2024</a>.
Li Auto attributes this adjustment to the temporary impact of an ongoing sales system upgrade, a strategic move intended to support its long-term growth.
It expressed conviction in completing its organizational upgrade before the launch of Li i8, enabling it to embrace the new product cycle effectively. The stock gained 53% in the last 12 months.
Li Auto <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45691082/tesla-rival-li-auto-will-release-2-new-suvs-this-year-ceo-li-xiang-hints-at-companys-first-sedan" rel="noreferrer noopener">plans to launch</a> two new SUVs in 2025 and may debut its first sedan if market conditions allow.
During its Q1 2025 earnings call, the company shared details about the Li i8, its first all-electric SUV designed for six passengers, and the smaller five-seat Li i6. Li Auto aims to release the i8 in July and the i6 in August.
The broader geopolitical landscape, particularly evolving U.S.-China trade relations, is influencing the semiconductor and EV sectors.
In the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45902627/us-listed-chinese-tech-and-ev-stocks-slide-as-trump-confirms-china-trade-deal" rel="noreferrer noopener">second week of June</a>, President&nbsp;Donald Trump confirmed a&nbsp;China trade deal&nbsp;after two days of negotiations in London, which sent the U.S.-listed Chinese stocks down. The U.S. plans to apply 55% tariffs on selected Chinese imports, while China will impose a 10% tariff rate on U.S. goods.
According to reports, U.S. and Chinese officials met in London for trade talks, which likely focused on rare earth minerals. Rare earth elements play significant roles in everything from smartphones to electric vehicles to fighter jets. The U.S. depends on China for ~70% of its imports of rare earth elements.
Furthermore, U.S. restrictions on China&#8217;s access to Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) technology have <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report" rel="noreferrer noopener">spurred Chinese automakers</a>, including Li Auto, to accelerate efforts to replace foreign semiconductors with domestic alternatives in their vehicles by 2027. At least two Chinese brands are reportedly aiming for mass production of cars using 100% domestic chips by 2026.
Price Action: LI stock is trading lower by 3.36% to $27.07 premarket at&nbsp;last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46116924/cyngn-stock-soars-135-after-partnering-with-nvidia-to-showcase-autonomous-industrial-vehicles" target="_blank" rel="noreferrer noopener">Autonomous Vehicle Solutions Provider Cyngn Stock Soars After Partnering With Nvidia &#8211; Here&#8217;s Why (UPDATED)</a></li>
</ul>
Photo by Robert Way via Shutterstock

Guidance

Tech

China's Li Auto Cuts Outlook As Xiaomi Challenges EV Giants

FOXO

FOXO Technologies Designates Series E Preferred Stock With Dual Dividends As Acquisition Currency And Capital Raise Tool

Nike shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

Telsey Advisory Group analyst Cristina Fernandez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Market Perform and maintains $70 price target.

Telsey Advisory Group Maintains Market Perform on Nike, Maintains $70 Price Target

Company Expects to Record Gain on Sale of Approximately $66 Million in Q2 Financial Results
LOS ANGELES, June 27, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) ("BRF" or the "Company"), a diversified financial services company, today announced it has sold its advisory services business, GlassRatner Advisory &amp; Capital Group, LLC (dba B. Riley Advisory Services) and B. Riley Farber Advisory Inc. (collectively "GlassRatner"), to funds managed by TorQuest Partners ("TorQuest") for $117.8 million.
BRF expects to record a gain on the sale of GlassRatner, which it acquired in August 2018, of approximately $66 million.

B. Riley Financial Sells Advisory Services Business, GlassRatner Advisory & Capital Group And B. Riley Farber Advisory To Funds Managed By TorQuest Partners For $117.8M

Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock.&nbsp; The closing of the Offer is subject to certain conditions, including the tender of Turnstone common stock representing at least a majority of the total number of outstanding shares, a minimum cash balance at closing, and other customary closing conditions.&nbsp; Immediately following the closing of the tender offer, Turnstone will be acquired by XOMA Royalty, and all remaining shares not tendered in the offer, other than shares validly subject to appraisal, will be converted into the right to receive the same cash and CVR consideration per share as is provided in the tender offer.&nbsp; Turnstone stockholders holding approximately 25.2% of Turnstone common stock have signed support agreements under which such stockholders have agreed to tender their shares in the Offer and support the merger transaction.&nbsp; The merger transaction is expected to close in August 2025.

TSBX

XOMA Royalty To Acquire Turnstone Biologics For $0.34 Per Share Plus CVR In August-Targeted Merger Deal

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $3 price target.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $3 Price Target

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) &#8220;very, very much,&#8221; adding that it is one of the few stocks in that group that he <a href="https://www.benzinga.com/quote/MPC">actually wants to own</a>.
Supporting his view, the company, on May 6, posted first-quarter total revenues and other income of $31.85 billion topping the consensus of $29.58 billion. Adjusted EPS loss stood at $(0.24), down from $2.58 a year earlier, beating the analyst consensus estimate of $(0.53).
Cramer said, &#8220;I have seen these speculative stocks go up and up, and I'm not going to make you sell Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) when a headline would cause that stock to double.&#8221;
On the earnings front, Aurora Innovation, on May 8, posted a first-quarter GAAP loss of 12 cents per share, in line with estimates.
Cramer said he is going with Brad Jacobs [Chairperson of QXO], when asked about QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>).
QXO, on June 20, proposed to acquire GMS for $95.20 per share in cash.
The Mad Money host said he likes Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), adding, &#8220;You got a good one there.&#8221;
Lending support to his choice, Truist Securities analyst Matthew Coad initiated coverage on Toast on June 2 with a Buy rating and announced a price target of $48.
Price Action:
<ul class="wp-block-list">
<li>Marathon Petroleum shares rose 1.1% to settle at $167.52 on Thursday.</li>
<li>Aurora Innovation shares gained 2.1% to close at $5.40.</li>
<li>QXO gained 1.4% to settle at $24.12 on Thursday.</li>
<li>Toast shares gained 2.4% to close at $42.49.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a></li>
</ul>
Image created using photos from Shutterstock.

Media

TOST

Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own

Rosenblatt analyst Chris Brendler maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and lowers the price target from $5.5 to $5.

HIVE

Rosenblatt Maintains Buy on HIVE Digital Technologies, Lowers Price Target to $5

On Thursday, June 26, U.S. markets closed higher as easing geopolitical tensions and supportive economic data boosted hopes for Federal Reserve rate cuts this year. Major indexes advanced in a broad rally, edging the S&amp;P 500 and Nasdaq closer to record highs.
Bank stocks led gains after a regulatory proposal, while Fed officials signaled openness to easing. Mixed economic signals, including weak consumer spending and strong orders, fueled speculation about the timing of rate cuts.
According to economic data, the U.S. first-quarter GDP was revised down to -0.5% from -0.2%, driven by a larger trade deficit from weaker exports. However, May factory orders jumped 16.4% to $343.6 billion, the biggest monthly gain since 2014, far exceeding expectations. Weekly jobless claims dropped by 10,000 to 236,000, defying forecasts of no change and signaling ongoing strength in the labor market.
Most S&amp;P 500 sectors rose, led by communication services, consumer discretionary, and energy. Real estate and consumer staples declined.
The Dow rose 0.94% to 43,386.84, the S&amp;P 500 was up 0.80% at 6,141.02, and the Nasdaq gained 0.97% to 20,167.91.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Friday, Japan&#8217;s Nikkei 225 closed 1.42% higher at 40,145.50, led by gains in the Real Estate, Banking, and Textile sectors.
Australia&#8217;s S&amp;P/ASX 200 was down 0.43% at 8,514.20, led by losses in the Financials, Healthcare, and A-REITs sectors.
India&#8217;s Nifty 50 was up 0.37% at 25,640.40, and the Nifty 500 gained 0.44% to 23,621.45.
China&#8217;s Shanghai Composite was down 0.70% at 3,424.23, and Shanghai Shenzhen CSI 300 fell 0.61% to 3,921.76.
Hong Kong&#8217;s Hang Seng closed the session 0.17% lower at 24,284.15.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was up 0.97%.
Germany&#8217;s DAX index gained 0.83%.
France&#8217;s CAC 40 rose 1.41%.
U.K.&#8217;s FTSE 100 index traded higher by 0.54%.
European stocks rose on U.S.-China trade progress and Middle East ceasefire optimism.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading higher by 0.72% at $65.71/bbl, and Brent was up 0.61% at $67.10/bbl.
Oil prices increased Friday but were on track for their biggest weekly drop since March 2023, as easing geopolitical tensions erased risk premiums. Focus shifted back to supply-demand fundamentals, with support from falling inventories and strong Chinese imports.
Natural gas rose 2.75% to $3.623.
Gold traded lower by 1.47% to $3,298.62, Silver fell 2.26% to $35.755, and Copper declined 1.34% to $4.9955.
Gold fell to a near four-week low as the Israel-Iran ceasefire reduced safe-haven demand and investors awaited key U.S. inflation data.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures rose 0.24%, the S&amp;P 500 gained 0.23%, and the Nasdaq 100 was up 0.31%.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index declined 0.04% to 97.26, USD/JPY was up 0.01% to 144.44, and USD/AUD gained 0.10% to 1.5290.
The U.S. dollar neared multi-year lows as markets priced in deeper rate cuts and a possible dovish Fed chair replacement.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Advances, Gold And Dollar Slip Further - Global Markets Today While US Slept

Gencor Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENC#NASDAQ">GENC</a>) reported quarterly earnings of $0.10 per share. This is a 52.38 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $20.921 million in sales this quarter. This is a 0.24 percent increase over sales of $20.871 million the same period last year.

GENC

Gencor Industries Q4 EPS $0.10 Down From $0.21 YoY, Sales $20.921M Up From $20.871M YoY

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Gencor Industries Says Net Revenue For Year Ended September 30, 2024 Increased 7.7% To $113.2M Million; Gross Profit Margin Was 27.7% In FY24 Compared To 27.6% YoY

NKE: 11% &#x7C; <a href="https://www.benzinga.com/node/46128469">Nike Q4 Earnings: Revenue Beat, EPS Beat, Headwinds Expected To Moderate Moving Forward, Company Playing 'Sport Offense'</a>
&nbsp;
BBLG: 188% &#x7C; <a href="https://www.benzinga.com/node/46136060">Bone Biologics Files USPTO Patent For rhNELL-1 Protein In Bone Regeneration Therapy</a>
&nbsp;
INMB: 130% &#x7C; <a href="https://www.benzinga.com/node/46127302">INmune Bio shares are trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.</a>

BBLG

INMB

Market-Moving News for June 27th

IPOs

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Reuters Reported Shein To File Confidential Draft Prospectus For Hong Kong IPO; Filing Expected To Be Made By Monday,

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) with a Buy and maintains $81 price target.

Reiteration

CRNX

HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target

Press Releases

SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Legal

Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Health Care

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Management

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Comments

Cassava Sciences

뉴스

파트너 / 기고자

벤징가 글로벌